In genotype @ null responders , daclatasvir plus twice-daily asunaprevir DUAL therapy is effective for most genotype @b patients , and daclatasvir , asunaprevir , and PegIFN/RBV QUAD therapy is effective for nearly all genotype @a and @b patients ; but neither DUAL nor TRIPLE therapy is effective for genotype @a patients .